EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Ronald Tutrone, Fred Saad, Daniel J George, Bertrand Tombal, James L Bailen, Michael S Cookson, Daniel R Saltzstein, Sarah Hanson, Bruce Brown, Sophia Lu, Mark Fallick, Neal D Shore

European Urology Oncology · 2024-08 · 7 (4) · 906-913

DOI: 10.1016/j.euo.2023.11.024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Urology Oncology, 2024-08. Verfasst von Ronald Tutrone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Chesapeake Urology, Towson, MD, USA. Electronic address: rtutrone@uniteduro.com. Hauptthemen laut MEDLINE: Leuprolide, Testosterone, Prostatic Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pfizer, Sumitomo Pharma Co Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In the HERO study, relugolix demonstrated sustained testosterone suppression superior to that of leuprolide acetate (97% vs 89%; difference 7.9% [95% confidence interval, 4.1-12%; p 280 ng/dl; ≥80% of baseline testosterone), serum levels of prostate-specific antigen and pituitary hormones, and adverse events. RESULTS AND LIMITATIONS: The cumulative incidence rate of testosterone recovery to >280 ng/dl at 90 d following drug discontinuation was significantly higher in the relugolix cohort (n = 137) than in the leuprolide acetate cohort (n = 47; 54% vs 3.2%; nominal p = 0.002). The median time to testosterone recovery was faster following relugolix treatment than with leuprolide acetate treatment (86.0 d vs 112.0 d). Compared with leuprolide acetate, more men treated with relugolix achieved ≥80% of baseline testosterone levels (39% vs 2.1%). Men ≤65 yr and those with baseline testosterone greater than the median had a higher incident rate of testosterone recovery. Adverse events were generally similar between treatment groups. One limitation is the short testosterone recovery follow-up period. CONCLUSIONS: Oral relugolix had faster and more complete recovery of testosterone to normal levels after treatment discontinuation than leuprolide acetate in a subset of men from the HERO study. The clinical implications of a faster testosterone recovery with relugolix may be significant for men being treated with androgen deprivation therapy and influence treatment decisions. PATIENT SUMMARY: The male hormone testosterone is reduced during androgen deprivation therapy for prostate cancer. Reduced testosterone levels cause side effects, impacting patient quality of life. When treatment is stopped, the side effects lessen over time as the levels of testosterone come back to pretreatment range (testosterone recovery). In this study, we found that the time to testosterone recovery was faster with relugolix than with leuprolide acetate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeuprolideTestosteroneProstatic NeoplasmsAntineoplastic Agents, HormonalHumansMaleAgedMiddle AgedProstate-Specific AntigenTreatment OutcomeAged, 80 and overPhenylurea CompoundsPyrimidinones

Stichwörter der Autor:innen

Advanced prostate cancerLeuprolideProstate-specific antigenRelugolixTestosterone recovery

Substanzen

LeuprolideTestosteroneAntineoplastic Agents, HormonalrelugolixProstate-Specific AntigenPhenylurea CompoundsPyrimidinones

Autor:innen und Institutionen

  • Chesapeake Urology, Towson, MD, USA. Electronic address: rtutrone@uniteduro.com.
  • University of Montreal Hospital Centre, Montreal, QC, Canada.
  • Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA.
  • Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium.
  • First Urology, Jeffersonville, IN, USA.
  • Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.

Förderung

  • Pfizer
  • Sumitomo Pharma Co Ltd

Zitieren

APA

Tutrone, R., Saad, F., George, D. J., Tombal, B., Bailen, J. L., Cookson, M. S., Saltzstein, D. R., Hanson, S., Brown, B., Lu, S., Fallick, M., & Shore, N. D. (2024). Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology, 7(4), 906-913. https://doi.org/10.1016/j.euo.2023.11.024

Vancouver

Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, et al. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. 2024;7(4):906-913. doi:10.1016/j.euo.2023.11.024

BibTeX
@article{Tutrone2024,
  author = {Tutrone, Ronald and Saad, Fred and George, Daniel J and Tombal, Bertrand and Bailen, James L and Cookson, Michael S and Saltzstein, Daniel R and Hanson, Sarah and Brown, Bruce and Lu, Sophia and Fallick, Mark and Shore, Neal D},
  title = {Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study},
  journal = {European Urology Oncology},
  year = {2024},
  volume = {7},
  number = {4},
  pages = {906--913},
  doi = {10.1016/j.euo.2023.11.024}
}
Kostenlos starten →